Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Lenalidomide is used to treat cancer and also some anaemia disorders
The group has a total of 320 ANDA approvals
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated